Physiomics plc (RVW1)

Overview

Physiomics Plc is a consulting firm that specializes in providing a range of quantitative pharmacology and computational biology services to pharmaceutical companies. Operating primarily within the United Kingdom, the United States, and the European Union including Switzerland, Physiomics combines its expertise in modeling, simulation, and data analysis to advance oncology research and development. The company leverages its proprietary Virtual Tumour predictive software to facilitate these processes. With a focus on the burgeoning field of personalized medicine, Physiomics is dedicated to developing innovative technology solutions. Founded in 2001, the company has established its headquarters in Oxford, United Kingdom, marking its place within the global pharmaceutical consulting sector.

Products and Services

Physiomics Plc offers a diversified portfolio of products and services targeted at enhancing pharmaceutical R&D through quantitative analysis and predictive modeling. These include:

• Modeling, Simulation, and Data Analysis Services: These services are core to Physiomics' offering, encompassing a wide spectrum of oncology research and development areas. The company utilizes state-of-the-art techniques and methodologies to analyze and predict cancer treatment outcomes, thereby facilitating more efficient and effective drug development processes.
• Virtual Tumour Predictive Software: A flagship product of Physiomics, the Virtual Tumour software is an advanced tool designed to simulate the growth and treatment of tumors in a virtual environment. This predictive modeling software aids researchers and pharmaceutical companies in understanding how different treatments might affect tumor growth and patient response, thereby streamlining the development of oncology drugs.
• Personalized Medicine Technology Development: Recognizing the growing importance of personalized medicine, Physiomics invests in the creation of innovative technology solutions tailored to individual patient needs. These efforts aim to enhance the precision and effectiveness of treatments by considering the unique genetic, environmental, and lifestyle factors of each patient.